The Dry Eye Zone

Rebecca's Blog


Drug news: Resolvyx / RX10045

According to a recent news report, Resolvyx Pharmaceutical (Bedford MA) is planning some dry eye drug trials for later this year.

Resolvyx are a little off the beaten track but on a track that many dry eye patients (especially auto-immune types) might find interesting, as it's all based on research into Omega 3s. They are apparently aspiring to develop drugs for a host of inflammatory auto-immune conditions.

Bedford biotech gains steam and attention
April 22, 2008

Resolvyx Pharmaceuticals Inc., based in Bedford, hopes to use recent scientific research on how omega-3 fatty acids work to develop a powerful new class of drugs to treat inflammatory diseases, ranging from asthma to cardiovascular problems....

Cofounder Charles Serhan, a scientist at Brigham and Women's Hospital in Boston, found evidence that omega-3s are important because the body uses them as raw materials to create another set of compounds, called resolvins, which help regulate the immune system. Without enough resolvins, the body has trouble stopping inflammation - a key way it fights off disease - after the threat has passed, contributing to an array of diseases, including arthritis....

So far, the company has only tested its drugs in rodents, such as asthmatic mice. But Resolvyx plans to test one compound, RX-10045, in humans this year to treat dry eye. And within the next year, it plans to launch clinical trials for another compound, RX-10001, to treat asthma. Resolvyx eventually hopes to determine whether the drugs can effectively treat more conditions, including rheumatoid arthritis, inflammatory bowel disease, cardiovascular diseases, and other eye problems.